Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx shifts to higher-margin products

This article was originally published in The Tan Sheet

Executive Summary

The maker of Zicam brand cough/cold and allergy relief products improved gross margins to 71 percent from 66 percent during fiscal 2009, thanks to a shift toward higher-margin Zicam cold and allergy products and away from multi-symptom cold and flu items. The success of Matrixx Initiatives' single-use swab applicators continues to be a boon for the firm, as its Zicam swabs now comprise about 35 percent of total company sales. A weak cold/flu season helped drop Matrixx's fourth quarter net sales 6.8 percent to $30.8 million, though net sales for its fiscal 2009 were up 10.6 percent to $111.6 million, the firm reported May 11. In a same-day earnings call, Chief Financial and Operating Officer Bill Hemelt said Matrixx projects 5 percent sales growth for fiscal 2010 and will ship two new Zicam cold remedy oral products in the second quarter. Hemelt, who also is acting president, said the Scottsdale, Ariz.-based firm is seeking a $30 million to $50 million acquisition in the OTC consumer health area to diversify beyond the cold/flu season (1"The Tan Sheet" Feb. 23, 2009, p. 5). ... NAD knocks down oral Zicam claims: Matrixx is advised to specify its oral Zicam products "may" reduce or lessen the severity of cold symptoms, since the supporting evidence applies to the brand's nasal gel products, the National Advertising Division says. The Council of Better Business Bureaus unit says May 12 the firm should additionally indicate whether a scientific study looked at its oral or nasal products. In response to NAD's conclusion, Matrixx says there is solid evidence behind oral zinc's ability to reduce cold severity, but will take the recommendation under advisement. Quigley, maker of Cold-Eeze products, challenged Zicam's claims
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS102921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel